仙琚制药
(002332)
| 流通市值：97.28亿 | | | 总市值：97.73亿 |
| 流通股本：9.85亿 | | | 总股本：9.89亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,237,007,358.82 | 2,137,847,609.83 | 1,037,926,735.62 | 4,123,418,584.19 |
| 营业收入 | 3,237,007,358.82 | 2,137,847,609.83 | 1,037,926,735.62 | 4,123,418,584.19 |
| 二、营业总成本 | 2,606,344,910.38 | 1,730,317,120.59 | 872,354,424.5 | 3,489,877,858.41 |
| 营业成本 | 1,468,589,836.32 | 965,397,843.09 | 465,931,030.78 | 1,943,124,328.97 |
| 税金及附加 | 24,008,593.36 | 16,615,958.48 | 5,588,195.03 | 36,865,620.32 |
| 销售费用 | 726,212,046.7 | 488,133,098.5 | 255,795,678.08 | 989,983,234.99 |
| 管理费用 | 226,132,174.54 | 158,809,744.66 | 82,389,215.65 | 281,225,497.28 |
| 研发费用 | 184,732,549.63 | 124,956,369.27 | 68,506,786.98 | 260,996,011.23 |
| 财务费用 | -23,330,290.17 | -23,595,893.41 | -5,856,482.02 | -22,316,834.38 |
| 其中:利息费用 | 1,386,946.1 | 937,734.73 | 596,189.18 | 3,366,369.19 |
| 其中:利息收入 | 24,443,304.43 | 19,079,749.68 | 7,311,074.32 | 38,275,568.98 |
| 加:投资收益 | 12,752,065.24 | 17,896,454.71 | 18,678,222.12 | -8,974,335.75 |
| 资产处置收益 | -730,693.12 | 61,575.16 | 64,293.16 | -1,476,053.55 |
| 资产减值损失(新) | -23,570,905.19 | -24,220,044.58 | - | -28,557,025.67 |
| 信用减值损失(新) | -7,696,654.31 | -5,223,685.32 | -5,992,160.45 | 5,037,743.56 |
| 其他收益 | 19,310,961.76 | 13,313,639.93 | 5,656,403.56 | 46,888,051.12 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 630,727,222.82 | 409,358,429.14 | 183,979,069.51 | 646,459,105.49 |
| 加:营业外收入 | 1,728,550.84 | 1,703,041.14 | 1,228,823.91 | 4,317,090.54 |
| 减:营业外支出 | 4,745,380.25 | 3,938,275.21 | 3,078,544.07 | 9,095,647.84 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 627,710,393.41 | 407,123,195.07 | 182,129,349.35 | 641,680,548.19 |
| 减:所得税费用 | 85,012,851.21 | 59,447,304.32 | 25,613,036.09 | 79,562,062.56 |
| 六、净利润 | 542,697,542.2 | 347,675,890.75 | 156,516,313.26 | 562,118,485.63 |
| 持续经营净利润 | 542,697,542.2 | 347,675,890.75 | 156,516,313.26 | 562,118,485.63 |
| 归属于母公司股东的净利润 | 530,180,818.31 | 339,722,437.63 | 151,121,862.92 | 563,083,493.15 |
| 少数股东损益 | 12,516,723.89 | 7,953,453.12 | 5,394,450.34 | -965,007.52 |
| (一)基本每股收益 | 0.54 | 0.34 | 0.15 | 0.57 |
| (二)稀释每股收益 | 0.54 | 0.34 | 0.15 | 0.57 |
| 八、其他综合收益 | -5,397,470.36 | -32,585,815.58 | -30,172,868.95 | 44,869,634.17 |
| 归属于母公司股东的其他综合收益 | -5,397,470.36 | -32,585,815.58 | -30,172,868.95 | 44,869,634.17 |
| 九、综合收益总额 | 537,300,071.84 | 315,090,075.17 | 126,343,444.31 | 606,988,119.8 |
| 归属于母公司股东的综合收益总额 | 524,783,347.95 | 307,136,622.05 | 120,948,993.97 | 607,953,127.32 |
| 归属于少数股东的综合收益总额 | 12,516,723.89 | 7,953,453.12 | 5,394,450.34 | -965,007.52 |
| 公告日期 | 2024-10-26 | 2024-08-27 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |